Overview

Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy

Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
A randomised controlled trial to investigate three methods to reduce early mortality in adults, adolescents and children aged 5 years or older starting antiretroviral therapy (ART) with severe immuno-deficiency. The three methods are: (i) increasing the potency of ART with a 12 week induction period using 4 antiretroviral drugs from 3 classes (ii) augmented prophylaxis against opportunistic/bacterial infections and helminths for 12 weeks (iii) macronutrient intervention using ready-to-use supplementary food for 12 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Anna Griffiths, MRC
Collaborators:
Department for International Development, United Kingdom
Medical Research Council
PENTA Foundation
Wellcome Trust
Treatments:
Albendazole
Azithromycin
Fluconazole
Isoniazid
Raltegravir Potassium